Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPO Safe Harbor Vulnerable? Senate Inquiry Targets Hospital Purchasers

This article was originally published in The Gray Sheet

Executive Summary

Senators with important ties to health reform negotiations have launched an inquiry into the common hospital group purchasing organization practice of collecting fees from device companies and other suppliers
Advertisement

Related Content

MDMA Presses For More Urgency In Changing FDA Mindset
MDMA Presses For More Urgency In Changing FDA Mindset
Federal Appeals Court Affirms GPO Contracting Tools
Federal Appeals Court Affirms GPO Contracting Tools
Device Firms Dig In Against Baucus Fee, Despite Class I, Revenue Exceptions
Device Firms Dig In Against Baucus Fee, Despite Class I, Revenue Exceptions
Senate Drafts Additional Bills To Regulate GPOs; MDMA Plans For ’06
GPOs May Spurn Anti-Competitive Contracts After Masimo v. Tyco – MDMA
GPOs May Spurn Anti-Competitive Contracts After Masimo v. Tyco – MDMA

Topics

Advertisement
UsernamePublicRestriction

Register

MT027816

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel